Inhibition of hepatic fibrogenesis: A review of pharmacologic candidates

J. Wu, A. Danielsson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Hepatic fibrosis is a dynamic process from chronic liver damage to cirrhosis. It is predominantly characterized by excessive accumulation of extracellular matrix (ECM) components in the liver, caused by both markedly increased production and unbalanced degradation of connective tissue components. Hepatocytes and non-parenchymal cells (Ito cells, Kupffer cells, and sinusoidal endothelial cells) are all involved in the process. Understanding the pathogenic mechanism of hepatic fibrosis is essential for effective anti-fibrotic treatment. Hepatocyte necrosis is an initiating and sustaining stimulus in the process. Activated Kupffer cells in liver inflammation and their released bioactive factors (for example, cytokines, free oxygen species) play a modulating role for cells participating in the process. Ito cells (lipocytes, fat-storing cells (FSC)) are considered to be the main cell type for overproduction of ECM, and activation of these cells induces excessive matrix production at higher rates than other cell types in the liver (1, 2). Consequently, Ito cell activation is critical for initiation of the liver fibrogenesis, and whether any anti-fibrotic therapy can affect Ito cell activation and the consecutive expression of various matrix substances is an important aim for investigations.

Original languageEnglish (US)
Pages (from-to)385-391
Number of pages7
JournalScandinavian Journal of Gastroenterology
Volume29
Issue number5
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Hepatic Stellate Cells
Liver
Fibrosis
Kupffer Cells
Adipocytes
Extracellular Matrix
Hepatocytes
Connective Tissue
Necrosis
Endothelial Cells
Cytokines
Oxygen
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Inhibition of hepatic fibrogenesis : A review of pharmacologic candidates. / Wu, J.; Danielsson, A.

In: Scandinavian Journal of Gastroenterology, Vol. 29, No. 5, 1994, p. 385-391.

Research output: Contribution to journalArticle

@article{4e4cebfed5f946deadd627715bcee233,
title = "Inhibition of hepatic fibrogenesis: A review of pharmacologic candidates",
abstract = "Hepatic fibrosis is a dynamic process from chronic liver damage to cirrhosis. It is predominantly characterized by excessive accumulation of extracellular matrix (ECM) components in the liver, caused by both markedly increased production and unbalanced degradation of connective tissue components. Hepatocytes and non-parenchymal cells (Ito cells, Kupffer cells, and sinusoidal endothelial cells) are all involved in the process. Understanding the pathogenic mechanism of hepatic fibrosis is essential for effective anti-fibrotic treatment. Hepatocyte necrosis is an initiating and sustaining stimulus in the process. Activated Kupffer cells in liver inflammation and their released bioactive factors (for example, cytokines, free oxygen species) play a modulating role for cells participating in the process. Ito cells (lipocytes, fat-storing cells (FSC)) are considered to be the main cell type for overproduction of ECM, and activation of these cells induces excessive matrix production at higher rates than other cell types in the liver (1, 2). Consequently, Ito cell activation is critical for initiation of the liver fibrogenesis, and whether any anti-fibrotic therapy can affect Ito cell activation and the consecutive expression of various matrix substances is an important aim for investigations.",
author = "J. Wu and A. Danielsson",
year = "1994",
doi = "10.3109/00365529409096827",
language = "English (US)",
volume = "29",
pages = "385--391",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Inhibition of hepatic fibrogenesis

T2 - A review of pharmacologic candidates

AU - Wu, J.

AU - Danielsson, A.

PY - 1994

Y1 - 1994

N2 - Hepatic fibrosis is a dynamic process from chronic liver damage to cirrhosis. It is predominantly characterized by excessive accumulation of extracellular matrix (ECM) components in the liver, caused by both markedly increased production and unbalanced degradation of connective tissue components. Hepatocytes and non-parenchymal cells (Ito cells, Kupffer cells, and sinusoidal endothelial cells) are all involved in the process. Understanding the pathogenic mechanism of hepatic fibrosis is essential for effective anti-fibrotic treatment. Hepatocyte necrosis is an initiating and sustaining stimulus in the process. Activated Kupffer cells in liver inflammation and their released bioactive factors (for example, cytokines, free oxygen species) play a modulating role for cells participating in the process. Ito cells (lipocytes, fat-storing cells (FSC)) are considered to be the main cell type for overproduction of ECM, and activation of these cells induces excessive matrix production at higher rates than other cell types in the liver (1, 2). Consequently, Ito cell activation is critical for initiation of the liver fibrogenesis, and whether any anti-fibrotic therapy can affect Ito cell activation and the consecutive expression of various matrix substances is an important aim for investigations.

AB - Hepatic fibrosis is a dynamic process from chronic liver damage to cirrhosis. It is predominantly characterized by excessive accumulation of extracellular matrix (ECM) components in the liver, caused by both markedly increased production and unbalanced degradation of connective tissue components. Hepatocytes and non-parenchymal cells (Ito cells, Kupffer cells, and sinusoidal endothelial cells) are all involved in the process. Understanding the pathogenic mechanism of hepatic fibrosis is essential for effective anti-fibrotic treatment. Hepatocyte necrosis is an initiating and sustaining stimulus in the process. Activated Kupffer cells in liver inflammation and their released bioactive factors (for example, cytokines, free oxygen species) play a modulating role for cells participating in the process. Ito cells (lipocytes, fat-storing cells (FSC)) are considered to be the main cell type for overproduction of ECM, and activation of these cells induces excessive matrix production at higher rates than other cell types in the liver (1, 2). Consequently, Ito cell activation is critical for initiation of the liver fibrogenesis, and whether any anti-fibrotic therapy can affect Ito cell activation and the consecutive expression of various matrix substances is an important aim for investigations.

UR - http://www.scopus.com/inward/record.url?scp=0028204118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028204118&partnerID=8YFLogxK

U2 - 10.3109/00365529409096827

DO - 10.3109/00365529409096827

M3 - Article

C2 - 8036452

AN - SCOPUS:0028204118

VL - 29

SP - 385

EP - 391

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 5

ER -